The expression of oestrogen receptor (ER)-β and its variants, but not ERα, in adult human mammary fibroblasts

C Palmieri, S Saji1, H Sakaguchi2, G Cheng2, A Sunters, M J O’Hare3, M Warner2, J-Å Gustafsson2, R C Coombes and E W-F Lam

Cancer Research-UK Laboratories and Section of Cancer Cell Biology, Department of Cancer Medicine, MRC Cyclotron Building, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
1Department of Surgery, Breast Oncology Unit, Tokyo Metropolitan Hospital, 113-8677, Tokyo, Japan
2Departments of Biosciences and Medical Nutrition, Karolinska Institute, NOVUM, S-141 86 Huddinge, Sweden
3University College London Breast Cancer Laboratory, Department of Surgery, Royal Free and University College Medical School, Riding House Street, London W1W 7EJ, UK

(Requests for offprints should be addressed to E W-F Lam; Email: eric.lam@imperial.ac.uk)

Abstract

Whilst oestrogen receptor (ER)-α and ERβ have been shown to be important in the development of the mammary gland, the cell-specific expression pattern of these two receptors within the human breast is not clear. Although it is well established that in the developing rodent mammary gland stromal ERα mediates the secretion of growth factors which stimulate the proliferation of the ductal epithelium, the expression of ERβ in human adult breast stromal fibroblasts is controversial, and the expression of ERα has not been properly defined. In the present study, we have evaluated the expression of ERα and ERβ by immunohistochemistry in normal tissue samples, and in purified human breast fibroblasts by Western blotting, RT-PCR analysis and ligand-binding sucrose gradient assay. Our data clearly demonstrated that ERβ variants, including ERβ1, ERβ2, ERβ5, ERβα and ERβins, but not ERα, are expressed in human adult mammary fibroblasts. These results are supported by the findings that an ERβ-selective ligand, BAG, but not the ERα high-affinity ligand oestradiol, can induce fibroblast growth factor-7 release and activate transcription from an oestrogen-responsive element promoter in these adult human mammary fibroblasts. Together, these observations revealed that, in the adult breast and in breast cancer, the proliferative signals derived from the stroma of adult mammary glands in response to oestrogen are not mediated by ERα and provide new insights into the nature of stromal–epithelial interactions in the adult mammary gland. In addition, the expression of these ERβ variants in cells where there is no ERα suggested that these ERβ splice forms may have functions other than that of modulating ERα activity.

Journal of Molecular Endocrinology (2004) 33, 35–50

Introduction

Oestrogen (e.g. oestradiol) plays a crucial role in regulating the growth and differentiation of the normal mammary gland and has an important role in the development and progression of breast cancer (Girdler & Brotherick 2000). The actions of oestrogen are mediated by its interaction with two oestrogen receptors, ERα and ERβ, which are ligand-activated nuclear transcription factors and members of the steroid/nuclear receptor superfamily (Kuiper et al. 1996, Parker 1998, Nilsson et al. 2001). Although ERα and ERβ are structurally similar (Brzozowski et al. 1997), there are significant differences in their ligand affinities and interaction with the transcriptional machinery, which result in important physiological and pharmacological differences in the signalling of the two receptors. Differential activation of the oestrogen-responsive element (ERE)-regulated and the activator protein-1 (AP-1)-controlled reporter genes by ERα and ERβ has been documented (Paech et al. 1997).

There are several mechanisms through which oestrogen stimulates growth of mammary
epithelium. One mechanism, which is crucial in the developing mammary gland, is the indirect effect of oestrogen on the mammary epithelium. In this case, oestrogen induces the mammary stroma to secrete growth factors, which in turn stimulate epithelial proliferation (Cunha et al. 1997). There is a considerable body of evidence showing that stromal ERα is involved in rodent mammary gland morphogenesis (Haslam & Shyamala 1981, Cunha et al. 1997). Recent studies in mice using chimeric tissue recombinations between ERα null and normal mice indicate that oestrogen-mediated proliferation of epithelial cells is dependent upon the presence of ERα in mouse mammary stromal cells, but not in epithelial cells (Yang et al. 1995, Bocchinfuso & Korach 1997). However, this is not an absolute requirement since the stroma from ERα null mice can support epithelial growth if oestrogen and progesterone are administered (Yang et al. 1995). Consistent with this notion is a recent immunohistochemical study on mouse transplanted human organoids showing that ERα is expressed in luminal epithelium but not the stroma (Parmar et al. 2002).

The adult mammary gland undergoes morphogenesis and remodelling throughout reproductive life. Morphogenesis is regulated by circulating steroids and polypeptide hormones, as well as by local epithelial–mesenchymal signals. The production and release of mesenchymal factors are under endocrine control. For example, the hepatocyte growth factor (HGF)/scatter factor (SF) promotes ductal outgrowth and tubule formation in the mammary gland (Niranjan et al. 1995), and the secretion of HGF/SF from the stroma has been shown to be increased by oestrogen (Sunil et al. 2002). Fibroblast growth factor (FGF7) (also termed keratinocyte growth factor (KGF)) is also another important mesenchymal-derived epithelial growth factor that has been shown to be regulated by oestrogen; however, there are species differences in its function on epithelial cells and its regulation by oestrogen. In humans, FGF7 stimulates both normal and malignant breast cancer epithelial cell proliferation (Palmieri et al. 2003). One report has indicated that the expression of FGF7 is not affected by oestrogen in normal breast stromal cells but is stimulated by oestrogen in stromal cells from breast cancers (Zhang et al. 1998). Administration of FGF7 to rats causes ductal proliferation, whilst in mice it results in cystic ducts (Yi et al. 1995). In mice, oestrogen was found to cause an increase in FGF7 in the mammary gland in vivo, but response was slow, and the dose needed was higher than that needed for growth of the uterus (Pedchenko & Imagawa 2000).

Although the evidence for the presence of ERα in the developing mammary stroma is strong, there is some question about which of the ERs is expressed in the stroma of the adult gland. ERα has been detected in stromal cells derived from tissues of fetuses, infants and young female individuals (Boyd et al. 1996, Keeling et al. 2000) but not stromal cells from adult samples (Boyd et al. 1996). By in situ hybridization, Sasano et al. (1999) detected ERα mRNA predominantly in ductal epithelial cells and also in some stromal cells. Others have also shown by immunohistochemical staining that there is a lack of ERα in both cancerous and normal human breast stromal cells (Walker et al. 1992, Leygue et al. 1999). Although ERβ is less well studied than ERα, there is evidence that ERβ is expressed in both epithelium and stroma (Crandall et al. 1998, Palmieri et al. 2002).

In the present study, we have investigated the presence of ERα and ERβ in breast stroma from normal breast tissue and from breast cancer. We purified fibroblasts from normal and malignant breasts and found that ERβ1, and its slice variants ERβcx (Ogawa et al. 1998) and ERβδ5, but not ERα, are expressed in these human breast fibroblasts. Furthermore, treatment of these fibroblasts with interleukin (IL)-1β and ERβ-specific agonist are more effective than oestrogen in stimulating fibroblasts to secrete the growth factor FGF7.

Materials and methods

Tissue samples

Human breast samples were obtained with the approval of the local ethics committee and consent from women who underwent breast reduction mammoplasty and surgery for carcinoma of the breast at Charing Cross Hospital and Central Middlesex Hospital, London, UK.

Immunohistochemical staining

Paraffin sections of breast tissue were obtained from the histopathology archive at Charing Cross...
Hospital, London. In all the immunostaining experiments, paraffin sections (4µm) were dewaxed in xylene and rehydrated through graded alcohol. Endogenous peroxidase was blocked by incubation for 15 min with a solution of 0·6% hydrogen peroxide and antigens were retrieved by microwave sections in 1 mM citrate buffer (pH 6·0) for 20 min at 800 W. Tissue sections were incubated for 10 min at room temperature with antibody diluent containing 5% normal rabbit serum, 0·1% bovine serum albumin and 0·1% sodium azide in phosphate-buffered saline (PBS). For ERβ immunostaining, a rabbit anti-human ERβ polyclonal (06-629) antibody from Upstate Biotechnology (Lake Placid, NY, USA) (1/100 dilution in antibody diluent) was applied to sections and incubated overnight at 4°C. ERβcx was detected by a specific antibody described recently (Saji et al. 2002). For ERα staining, monoclonal mouse anti-ERα (1D5; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was applied at a dilution of 1/500 in antibody diluent and the sections incubated overnight at 4°C. After incubation with the primary antibodies, the sections were rinsed in PBS with 0·05% Tween 20 prior to addition of the appropriate peroxidase-conjugated secondary antibody in PBS. As secondary antibodies, peroxidase-conjugated rabbit anti-mouse IgG (Dako, Ely, UK) and goat anti-rabbit IgG (Sigma, Poole, Dorset, UK) were used at dilutions of 1:100. After incubation for 1 h at room temperature the secondary antibodies were washed off with PBS with 0·05% Tween 20. Colour staining was developed with hydrogen peroxide and 3,3'-diaminobenzidine tetrahydrochloride (DAB; Dako). After colour development, the sections were also counterstained with Mayer’s haematoxylin, dehydrated through graded alcohol to xylene, and mounted with Pertex (Histolab, Havershill, UK).

**Expression of ERω/ERβi in human mammary fibroblasts · C PALMIERI and others**

**Breast fibroblast purification and culture**

Breast fibroblasts were prepared from reduction mammoplasty and breast carcinoma tissues as described previously (Gomm et al. 1995). The tissues were first assessed by histopathologists to ascertain the exact pathological status before being used for breast fibroblast preparations. Briefly, 0·5 cm² breast tissue was digested overnight with 1 mg/ml collagenase (Sigma) and 1 mg/ml hyaluronidase (Sigma) in RPMI 1640 (Gibco-BRL, Life Technologies Inc., Paisley, UK) plus 5% fetal calf serum (FCS) at 37 °C, followed by centrifugation at 150 g for 5 min. After removing the lipid layer, the tissue suspension was subjected to three sedimentations at 1 g (or under gravity) to enrich for the ductal and lobular elements. The supernatants containing single cells (including blood cells, fibroblasts and endothelial cells) were removed and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco-BRL, Life Technologies Inc.) supplemented with 10% FCS, 2 mM glutamine, 100U/ml penicillin and 0·1 mg/ml streptomycin to positively select for stromal cells. The blood cells in the cell suspension were eliminated by three rounds of depletion using anti-common acute lymphoblastic leukaemia antigen (CALLA/CD10; Sera-Lab, Loughborough, UK) conjugated to 4·5 µm Dynabeads (Dynal, Bromborough, UK) according to the manufacturer’s protocol. Dynabead-conjugated rat monoclonal anti-epithelial membrane antigen was then used to eliminate epithelial and myoepithelial cells as described (Gomm et al. 1995). The purified breast fibroblasts were then expanded and used for RNA and protein preparation. One of the fibroblast lines (line 8) is conditionally immortalized and has been described previously (O’Hare et al. 2001).

**RNA preparation and cDNA production by RT**

Total RNA was isolated using the RNeasy kit (Qiagen, Crawley, UK) and quantified by absorbance at 260 nm. Total RNA (2 µg) was reverse transcribed in a 12 µl reaction mixture composed of 10 U MMLV reverse transcriptase (Gibco-BRL, Life Technologies Inc.), 2 mM dNTPs, 6·7 mM MgCl₂ and 5µM random hexamer primers. The mixture was incubated at 40°C for 60 min, followed by heating at 95°C for 10 min.

**PCR**

PCR was carried out using the Gene Amp PCR System 2400 or 7700 gene amplifier (Perkin-Elmer, Beaconsfield, UK). The PCR of 50 µl consisted of 3 µl cDNA (corresponding to 500 ng RNA), 1 × PCR buffer (Perkin-Elmer), 2·5 mM MgCl₂, 0·2 mM dNTPs, 0·5 units Taq polymerase (Perkin-Elmer) and 1µM of each of the sequence specific primers. At each cycle, the PCR was denatured at 94°C for 30s, annealed at specific
temperature/time and extended at 72 °C for 60 s. The final extension was at 72 °C for 3 min at the completion of the last cycle. The nucleotide sequences, annealing temperatures, reaction cycles and predicted sizes of the cDNA products of the primers used and names were as follows.

**β-actin** (1) PCR: forward 5’-GTGCACCTC GCGCGATGCTG-3’; reverse 5’-CCTCACCAG GCGGGCTACAG-3’ (58 °C, 35 cycles, 500 bp).

ERα PCR: EX2U forward 5’-GGAGACATGA GAGCTGCCAC-3’; EX4L reverse 5’-CCAGC AGCATGTCGAAGATC-3’ (58 °C, 40 cycles, 292 bp).

ERβ PCR: forward 5’-TGTTACTGTGACACAGG-3’; reverse 5’-AGCCACACC TTCAACCATTCCCAC-3’ (60 °C, 40 cycles, 200 bp).

ERα WT (wild type)/βins PCR: forward (LBD U) 5’-GAGGACAGCTTTGACCACC-3’; reverse (LBD L) 5’-GGGCTTGACACAGAGATATTC-3’ (57 °C, 38 cycles, 247 bp for WT and 300 bp for βins).

ERα WT/Δ5 PCR: forward δ 55’-ATGATGCTCCTGGACAAAG-3’; reverse LBD 5’-GGGCTTGACACAGAGATATTC-3’ (57 °C, 38 cycles, 327 bp for WT and 188 bp for Δ5).

ERβ WT/βcx/β5 PCR: forward (1U) 5’-CGATGCTTGGTTGGGTGTAG-3’; reverse (1 L) 5’-GCCCTCTTTGCTTTACTGTC-3’; reverse (2 L) 5’-CTTTAGGCCACCGAGTTG ATT-3’ (57 °C, 38 cycles, 268 bp for WT, 214 bp for βcx and 295 bp for β5).

Cytokeratin 19 PCR: forward 5’-TCCGCCC GCTTGGTTGCTCCCTCGT-3’; reverse 5’-AG CATCCTCCGGTTCTCTCGC-3’ (69 °C, 30 cycles, 488 bp).

β-actin (2) PCR: forward 5’-CTGGGCACCA CACCGTTCTAC-3’; reverse 5’-GGGACAGT GTGGGTGAC-3’ (58 °C, 35 cycles, 237 bp).

All PCR products were resolved on 2% agarose gel by electrophoresis in Tris-acetate-EDTA buffer in the presence of 0.5 μg/ml ethidium bromide. The DNA bands were visualised in the presence of u.v. illumination.

### Western blot analysis and antibodies

Whole cell extracts were prepared by lysing cells with four times packed cell volume of lysis buffer (1% Nonidet P-40, 100 mM NaCl, 20 mM Tris, pH 7.4, 10 mM NaF, 1 mM sodium orthovanadate and protease inhibitors (‘Complete’ purchased from Roche, Lewes, UK) on ice for 15 min. Protein yield was quantified by Bio-Rad Dc protein assay kit (Bio-Rad, Hemel Hempstead, UK). One hundred micrograms of lysate were separated by SDS-PAGE, transferred to nitrocellulose membranes and recognised by specific antibodies. The ERβ (06-629) and ERα (ID5) antibodies used for immunostaining did not give the best results for Western blotting, and the ERα (F-10) antibody and the polyclonal ERβ (LBD) were used instead for Western blotting. The mouse monoclonal ERα (F-10) antibody and the anti-actin polyclonal antibody were purchased from Santa Cruz Biotechnology. The rabbit polyclonal ERβ (LBD) and ERβ cx antibodies have been described previously (Saji et al. 2000, 2002) and were raised against the ligand-binding domain of ERβ1 protein and the C-terminus of ERβ cx respectively. The antibodies were detected using horseradish peroxidase-linked goat anti-mouse or anti-rabbit IgG (Dako) and visualised by the enhanced chemiluminescent detection system (Amersham Pharmacia Biotech, Amersham, Bucks, UK).

### Sucrose density gradient assay

Sucrose density gradient assay was performed essentially as described previously (Jensen et al. 1968, Palmieri et al. 2002). Cell pellets frozen on liquid nitrogen were pulverised in a dismembrator (Braun Melsungen, Melsungen, Germany) for 45 s at 1800 r.p.m. Pulverised cells (100 μg/ml) were added to a buffer consisting of 10 mM Tris-HCl, pH 7.5, 1.5 mM EDTA and 5 mM sodium molybdate. Cytosol was obtained by centrifugation of the homogenate at 75 000 g for 1 h in a 70Ti rotor (Beckman Instruments, High Wycombe, UK) at 4 °C. Cell extracts were incubated for 2 h at 0 °C with 10 nM [3H]oestradiol (Amersham International, Amersham, Bucks, UK) in the absence or presence of 50-fold excess of unlabelled oestradiol (Sigma) as described previously (Saji et al. 2000), and the unbound oestradiol was removed with dextran-coated charcoal. Samples (100 μl) were layered on 4 ml sucrose density gradients (10–30% (w/v)) sucrose in 10 mM Tris–HCl, 1.5 mM EDTA, 1 mM -monothioglycerol (Sigma) and 10 mM KCl) and centrifuged for 16 h at 300 000 g in an SW-60Ti rotor (Beckman Instruments) at 4 °C. Successive 100 μl fractions were collected from the
bottom by paraffin oil displacement and assayed for radioactivity by liquid scintillation counting. For Western blotting, fractions were first precipitated with trichloroacetic acid, then resuspended in methanol and incubated on dry ice for 30 min. The protein was recovered by centrifugation. Pellets were dissolved in SDS sample buffer, resolved by SDS-PAGE and subjected to Western blot analysis.

FGF7 release and transfection assays

Purified human breast fibroblasts were normally cultured in DMEM with 10% FCS, 2 mM glutamine, 100 U/ml penicillin and 0·1 mg/ml streptomycin. To assess the effects of different growth factors and ligands on the production of FGF7, the purified breast fibroblasts were incubated with different cytokines and ER ligands in breast culture medium (BCM) consisting of 1:1 mix of DMEM (without phenol red) and Ham’s F12 supplemented with 15 mM HEPES, 2 mM glutamine, 5 µg/ml insulin, 10 µg/ml apo-transferrin, 100 µM ethanolamine, 1 µg/ml hydrocortisone, 10 ng/ml epidermal growth factor, 100 U/ml penicillin, 0·1 mg/ml streptomycin, 50 U/ml polymyxin B and 2·5 µg/ml amphotericin (all from Sigma) (Gomm et al. 1995, 1997). The amount of FGF7 produced by the fibroblasts in the culture medium was measured using the human KGF Quantikine Kit (R&D Systems, Abingdon, UK) according to the manufacturer’s protocol. The human KGF Quantikine Kit was an ELISA-based quantification assay, and the absorbance was measured at a wavelength of 450 nm within 30 min using a 550 plate reader (Bio-Rad). IL-1β was purchased from R&D Systems. Oestradiol, tamoxifen and kaempferol (3,4’,5,7-tetrahydroxyflavone) were obtained from Sigma and ICI 182,780 from Trocris Cookson Inc. (St Louis, MO, USA). The ER selective agonist BAG (L-851 057) (Cheng et al. 2004) was supplied by Merck, West Drayton, UK. All the ER ligands were prepared in ethanol and added at the concentrations indicated.

For transfection assays, an ERE-driven chloramphenicol acetyltransferase (CAT) gene reporter plasmid was co-transfected with a pSG5-β-galactosidase transfection control into the human mammary fibroblasts cultured in BCM using the calcium phosphate precipitation method (Lam et al. 1995). These plasmids have all been described previously (Ali et al. 1993, Chen et al. 1999). The transfected human mammary fibroblasts were then treated as described for FGF7 release assay and harvested for CAT and β-galactosidase after 3 days. The CAT expression was quantified using a CAT ELISA kit (Roche Diagnostics GmbH) as described by the manufacturer.

Results

Immunohistochemical localisation of ERα and ERβ in human breast tissues

Immunohistochemical staining of formalin-fixed paraffin-embedded sections of normal human breast tissue are shown in Fig. 1. As previously reported (Jensen et al. 2001), ERα was expressed primarily in the epithelium, but not in the stroma (Fig. 1A), while staining for ERβ was observed in both the epithelium and stroma (Fig. 1B and C). This staining pattern was not detected with a non-specific control antibody (Fig. 1D and E) and the staining was blocked by 100-fold excess of the peptide used as antigen (Fig. 1F). The ERβ antibody used in Fig. 1A–F was raised against an N-terminal peptide common to both ERβ1 and ERβcx. In order to investigate the cellular localization of ERβcx, a specific antibody raised against the unique amino acid sequence coded for by the ERβcx-specific exon was used. The result showed that as shown in Fig. 1G and H ERβcx is also present in both epithelial cells and fibroblasts of breast (Fig. 1I–L).

Expression of ERα and ERβ mRNA in human breast fibroblasts

The expression of ERα and ERβ mRNA was investigated by RT-PCR analysis. RNA was extracted from a panel of human breast fibroblasts purified from normal breast tissue derived from reduction mammoplasty as well as fibroblasts from women who had undergone surgery for malignant breast tumours. The panel consisted of seven normal (lines 1–7) and six malignant (lines 9–14) fibroblasts, as well as an immortalised human fibroblast cell line (line 8) which was derived from a reduction mammoplasty. For comparison, we also included the malignant breast epithelial cell lines MCF-7, MDA-MB-231 and T47D for ERα-specific RT-PCR, and MCF-7 and MDA-MB-231 for ERβ RT-PCR (Fig. 2). β-actin was used as a

www.endocrinology.org
Figure 1 Immunostaining of normal human breast tissues for ERα and ERβ expression. Representative photomicrographs of immunohistochemical staining of breast sections using DAB as substrate. All micrographs were at 200× magnification unless indicated. (A) Normal human breast tissue was stained with anti-ERα (1D5) antibody. Positive staining was detected in epithelial cells only. (B) Normal human breast tissue was stained with an anti-ERβ (06-629) antibody. Staining is observed in the ductal epithelial cells and stromal fibroblasts. (C) Normal human breast stroma was stained with the anti-ERβ antibody. (D) Normal human breast tissue was stained with an unrelated antibody, demonstrating no ductal epithelial and stromal staining. (E) Normal human breast tissue was stained with the anti-ERβ antibody, showing positive staining for epithelial cells and some stromal cells. (F) Normal breast tissue (as in E) was stained with the anti-ERβ antibody in the presence of antigenic peptides. (G) Control normal prostate tissue was stained with the anti-ERβ antibody, showing positive staining for epithelial cells only. (H) Normal prostate tissue was stained with the anti-ERβ antibody in the presence of the antigenic (blocking) peptides, showing no sign of staining. (I) Normal human breast tissue was stained the anti-ERβ antibody (LBD) (100× magnification). (J) Normal human breast tissue was stained with an anti-ERβcx-specific antibody (Saji et al. 2002) (100× magnification). (K) Normal human breast tissue was stained with the anti-ERβcx-specific antibody. (L) Normal human breast tissue was stained with the anti-ERβcx-specific antibody in the presence of the antigenic peptides, showing little sign of staining. Nuclear localisation is observed in all the positive staining.
control for cDNA synthesis, PCR efficiency and gel loading.

The ERα status of the human fibroblasts was investigated using RT-PCR with PCR primers recognising sequences within regions A/B and D of human ERα mRNA respectively. These primers produced a product of 292 bp from the cDNA derived from MCF-7 and T47D cells. This band indicated the presence of ERα mRNA (Fig. 2). The negative control was the MDA-MB-231 cell line which is known not to express ERα and with which no PCR signal was found. With cDNA from fibroblasts from either normal or malignant human breasts, no ERα-specific band was amplified (Fig. 2). With ERβ-specific primers, a PCR product of the expected size, 200 bp, was produced in all the samples from both the normal and malignant human breast fibroblasts and the two breast epithelial cell lines, MCF-7 and MDA-MB-231. It is notable that a minor but higher molecular weight PCR product was also obtained using the ERβ primers F and B. This represents a splice variant with an insertion into the C and D regions, which are important for DNA binding and dimerisation.

Human breast fibroblasts were prepared from an established technique in our laboratory and their morphological appearance was examined and subsequently confirmed to be that of fibroblasts and

---

**Figure 2** Expression of ERα, ERβ, cytokeratin 19 and β-actin mRNA in purified breast fibroblasts and breast epithelial cancer cell lines. Total RNA extracted from 14 normal and malignant breast fibroblasts, and the epithelial cancer cell lines MCF-7 and MDA-MB-231 was reverse transcribed and analysed for the expression of ERα, ERβ, cytokeratin 19 and β-actin mRNA by PCR using the primers shown. The ER-positive cell line T47D was also included as an extra positive control for ERα PCR. Schematic diagrams of the exons and functional domains of ERα and ERβ are shown in the upper panel.
not epithelial cells. Cytokeratin 19 was used as a marker for epithelial cells to assess the degree of contamination of fibroblasts with epithelial cells. RT-PCR analysis with cytokeratin 19 primers produced a predicted product of 500 bp from the MCF-7 and MDA-MB-231 cell lines, but not from any of the purified human breast fibroblasts, indicating that the human fibroblasts isolated were not contaminated with epithelial cells (Fig. 2).

**Expression of ERβ variant mRNAs in human breast fibroblasts**

The expression of ERβ splice variants in populations of purified breast fibroblasts was investigated by PCR analysis (Fig. 3). Three categories of variants were investigated: ERβins-, a splice variant with an insert of 54 bp in the ligand-binding domain (Chu et al. 1997, Petersen et al. 1998) commonly found in rodents but not in human tissues; ERβ5, which lacks exon 5; ERβcx, in which the C-terminal 61 amino acids are replaced by a unique 26 amino acid sequence; and ERβ5 which is a truncated receptor consisting only of amino acids 409–472. The 14 fibroblast samples were processed separately in two subgroups. The expression levels of various ERβ isoforms were judged by the relative intensity of the bands between different samples within the same subgroup.

---

**Figure 3** Expression of ERβ variants in purified breast fibroblasts and breast epithelial cancer cell lines. The expression of ERβ variants ERβ1, ERβcx, ERβ5 and ERβins mRNA transcripts in 14 normal and malignant breast fibroblasts, and the epithelial cancer cell lines MCF-7 and MDA-MB-231 was analysed by RT-PCR using splice variant-specific primers. Schematic diagrams of the structures and functional domains of common ERβ splice variants are shown in the upper panel. β-actin cDNA was amplified in parallel. a.a., amino acids; wt, wild type.
The presence of ERβins was examined using the primer pair LBD U and LBD L, complementary to sequences in exon 5 and exon 6 of the ERβ gene respectively. In only one cDNA sample was a band corresponding to ERβins amplified. The one positive signal seen in lane 7 could represent a novel splice variant arising from a rare human mutation.

For detection of ERβδ5 variants, primers recognising sequences in exon 4 and exon 6 of the gene were used. The PCR result showed that in all the normal and malignant breast fibroblasts there was a normal ERβ mRNA with an intact 5th exon. However, as revealed by the presence of the shorter 188 bp (δ5-specific) PCR product, the normal fibroblasts in lanes 3 and 7 as well as the malignant line 12 also expressed the ERβ splice variant which lacks the 5th exon. This ERβδ5 splice form was also present in the MDA-MB-231, but not the MCF 7 and T47D epithelial cell lines. It is notable that these δ5-specific primers also span the region of the ligand-binding domain and thus include the region where ERβins would be detected. The presence in the normal fibroblast in lane 7 of a PCR product about 50 bp longer than expected confirmed that there was a novel mRNA in this sample.

Detection of the ERβcx and ERβδ5 variants by PCR involved the use of three primers in the same reaction, namely 1U, 1 L and 2 L, corresponding to sequences in exon 7 and in exon 8 present only in ERβcx and ERβδ5 mRNA respectively. The PCR results showed that all but two of the fibroblast cell lines possessed the ERβ1 C-terminal sequence. Only the normal fibroblast (lane 3) and the malignant (lane 9) lacked the sequence at the 3′ end of ERβ1. Interestingly, all of the human breast fibroblast lines, both normal and malignant, contained the ERβcx variant, as did the epithelial cell lines. ERβδ5 transcript was only expressed in two of the six fibroblast cell lines (11 and 12) derived from malignant breast tumours and in two of the eight normal fibroblast cell lines (5 and 8) derived from normal fibroblasts.

Expression of ERβ but not ERα protein in human breast fibroblasts

Cell lysates were prepared from the majority of the samples and subjected to Western blot analysis for ER expression (Fig. 4). The expression of ERα and the two major ERβ variants (ERβ1 and ERβcx) in breast fibroblasts was investigated with specific antibodies. Western blots for ERα revealed that only the cell line MCF-7 expressed ERα of the expected molecular weight of 66 kDa. MDA-MB-231 (a known ERα-negative breast epithelial cell line) and all of the normal and malignant human breast fibroblasts were negative for ERα. Western blot analysis with an ERβ antibody (LBD) raised against the ligand-binding domain of ERβ1 (Saji et al. 2000, 2002) identified a predominant ERβ product of 57 kDa, corresponding to ERβ1, at significant levels in all but two of the fibroblasts. It is notable that the ERβ expression levels in these two fibroblast lines 3 and 9 were extremely low when compared with the other fibroblast lines. This was consistent with our previous RT-PCR results showing that both lines 3 and 9 expressed very low levels of ERβ1. Unlike ERβ1, ERβcx appeared to be expressed in all breast fibroblasts studied, again consistent with the RT-PCR result. This result also demonstrated that the epithelial cell lines MCF-7 and MDA-MB-231 expressed both ERβ1 and ERβcx. These data confirmed that, at the protein level, human fibroblasts express only ERβ and not ERα.

Expression of ERβ with little or no oestrogen-binding activity in breast fibroblasts

We next examined the expression levels and binding capacity of ERα and ERβ in the human breast fibroblasts and the MCF-7 and MDA-MB-231 cell lines using sucrose density gradient centrifugation assay with [3H]oestradiol as ligand (Palmieri et al. 2002). Consistent with previous data, the ERα-containing radiolabelled 8S peak was only detected in the extract from the MCF-7 cells, and not in extracts from the human breast fibroblasts or the ERα-negative MDA-MB-231 cell line (Fig. 5). This expression pattern was confirmed by Western blotting of sucrose density gradient fractions corresponding to a sedimentation rate of 8S. Although it has been shown that ERβ sediments on sucrose gradients as a 4S peak (Weihsa et al. 2001, Palmieri et al. 2002), no specific 4S oestradiol-binding peak was observed for the human breast fibroblasts or the MCF-7 and MDA-MB-231 cell lines. Western blotting of the fractions corresponding to the 4S region of the gradient
showed that ERβ was present in these fractions. One interpretation of these results is that ERβcx which does not bind oestradiol is the dominant ER in the human breast fibroblasts as well as the MCF-7 and MDA-MB-231 cell lines. When the 4S sucrose gradient fractions were probed for ERβcx expression, it was found that the human breast fibroblasts and the MCF-7 and MDA-MB-231 cell lines all expressed the ERβcx protein.

**Role of ER and oestrogen in adult human mammary fibroblasts**

FGF7 is a breast stromal fibroblast-derived mitogen that stimulates mammary epithelial cell growth. Previous reports have indicated that the expression of FGF7 mRNA and protein in mammary gland is oestrogen regulated (Zhang et al. 1998, Pedchenko & Imagawa 2000). To obtain further information on the functional role of the ER species present in the human breast fibroblasts, the effects of various ERα and β ligands on FGF7 release from these fibroblasts were analysed by ELISA (Fig. 6.). Consistent with previous reports (Palmieri et al. 2003), treatment with IL-1β induced a significant increase in the release of FGF7 (t-test, P<0.001), indicating that these human breast fibroblasts were capable of producing FGF7. When fibroblasts in culture were treated with various physiological concentrations of oestradiol (10⁻¹⁰, 10⁻⁹, 10⁻⁸), there was no significant increase in release of FGF7 into the culture medium. Similarly, the anti-oestrogens tamoxifen and ICI 182,780 had little effect on the release of FGF7. This is in agreement with the earlier sucrose gradient oestradiol-affinity assay showing that the ERβ in human breast fibroblasts has little oestrogen-binding activity. Interestingly, when the breast fibroblasts were incubated with the ERβ-selective ligand, BAG (Cheng et al. 2004), which has 100× higher affinity for ERβ compared with ERα, significant levels of FGF7 release were observed (t-test, P<0.001). Similarly, another ligand, kaempferol (Kuiper et al. 1998), which has been demonstrated to have high affinity for ERβ, also increased FGF7 production in human breast fibroblasts (t-test, P<0.001). We next transfected into these breast fibroblasts an ERE-responsive reporter construct to assay for ERE-dependent transcriptional activity in the...
The results showed that while oestrogen failed to significantly transactivate the ERE-dependent reporter (t-test, \( P=0.064 \)), BAG could activate transcription from this construct (t-test, \( P=0.006 \)). These findings supported the notion that human breast fibroblasts express ER\( \beta \) but not ER\( \alpha \), and that ER\( \beta \) species present in the human breast fibroblasts have low oestradiol-binding activity and little function in oestrogen action.

**Figure 5** Total ligand-binding sucrose density gradient and Western blot analysis of human breast fibroblast, MCF-7 and MDA-MB-231 cell lysates. Human breast fibroblast, MCF-7 and MDA-MB-231 cell lysates were subjected to sucrose density gradient assay using \(^{[3]}\)H-oestradiol as ligand. Fractions (100 \( \mu l \)) were collected from the bottom of the gradients and assayed for radioactivity by liquid scintillation counting. A representative typical human breast fibroblast reactivity profile is shown (A). Parallel control gradients for human breast fibroblast, MCF-7 and MDA-MB-231 were performed in the presence of 50-fold excess unlabelled oestradiol. These profiles overlapped with those of MDA-MB-231 and human breast fibroblasts (data not shown). Fractions corresponding to sedimentation rates of 8S (fractions 6–20) and 4S (fractions 24–30) were pooled and subjected to Western blot analysis for ER\( \alpha \), ER\( \beta \) (using LBD antibody) and ER\( \beta \)cx expression (B).
Discussion

Our previous immunohistochemical studies have suggested that ERβ but not ERα is expressed in human breast stroma (Jensen et al. 2001, Palmieri et al. 2002). In the present study, we further confirmed this observation with more detailed immunohistochemical staining, using additional breast tissue samples and ERβ-specific antibodies. More importantly, using purified populations of adult female human breast fibroblasts, we went on to study the expression of ERα and ERβ using RT-PCR, Western blot analysis and sucrose density gradient assay, and again found that ERβ but not ERα was expressed in both normal and malignant human breast fibroblasts. This is the first time that purified populations of breast fibroblasts have been analysed for their ERα and ERβ content and unique information is provided regarding the expression of ERβ variants in human breast fibroblasts. We have previously found a predominant expression of ERβcx, a splice variant which does not bind oestrogen, and which is a dominant repressor of ERα with less effect on ERβ1 (Ogawa et al. 1998).

At first glance, the absence of ERα from breast stroma might seem to be in conflict with some published data (Boyd et al. 1996, Keeling et al. 2000, Koerner et al. 2001), but it appears that several studies showing the presence of ERα in human breast stroma were done on developing gland, fetal, newborn or young female individuals (Keeling et al. 2000) and this prompts us to speculate that ERα is expressed in the stroma of the developing gland and that there is a switch to ERβ as the gland matures. Consistent with this explanation, Boyd et al. (1996) noted that the number of fibroblasts positive for ERα decreased as the glandular tissue became more differentiated/mature, and Koerner et al. (2001) found that ERα-positive fibroblasts were more readily detectable in young teenage females compared with older subjects. In the rat mammary gland, administration of growth hormone has been shown to result in expression of ERα in mammary stromal cells (Feldman et al. 1999). Although at present there are no data on the regulation of the human stromal ERα, it is possible that stimulation by growth hormone, or another hormone expressed during periods of growth of the organism, may explain these age-related phenomena, and aberrant expression of these stochastic factors could account for some of the instances when ERα has been found in the stroma of adult human breast.

Previous studies using mouse models have shown that epithelial–stromal cell interactions are important for the normal development and function of the mammary gland. Cuhna et al. (1997) have found that the growth of mammary ducts in mice requires the presence of ER in the stroma. In addition, it has been shown that the effects of oestrogen on proliferation in the mammary epithelium of mice are modulated by the mammary stroma (Woodward et al. 1998), and a similar observation has been documented in the uterus (Cooke et al. 1997). A possible mechanism for the effect of oestrogen on the mammary epithelium which is mediated by the stroma has been put forward recently by Zhang et al. (2002). These authors found that treatment of murine fibroblasts with oestrogen caused an increase in the production of HGF, which caused proliferation of epithelial cells. In light of the present finding that ERβ but not ERα is expressed in adult human breast fibroblasts, the mesenchymal–epithelial relationship as well as the possible effects of oestrogen acting indirectly on...
the epithelium via stromal ER also need to be re-evaluated. Moreover, the present data indicate that some of the previous studies on mouse stroma–epithelium interactions may not be applicable to the adult human breast situation.

Besides demonstrating that ERβ is the sole ER isotype expressed in breast fibroblasts, our RT-PCR and Western blotting results also showed that ERβ1 and ERβcx are the predominant variants in breast fibroblasts, with ERβcx expressed in all fibroblasts examined and ERβ1 in all but two of the fibroblasts. It is interesting to note that ERβcx was expressed at a higher frequency in these human breast fibroblasts than ERβ1, suggesting that ERβcx could be the major form of ERβ in breast fibroblasts. The other variants, including ERβ5 and ERβδ5, were also detected in the fibroblasts, but they were present at low levels in human breast fibroblasts. Our result also identified a potential rare insertion variant present in one of the fibroblast cell lines (line 7); however, its functional significance requires further investigation. No significant difference in ERβ variant expression was observed between normal and malignant fibroblasts. Although ERβins is frequently expressed in rat mammary glands (Saji et al. 2001), our data showed that it is not normally detected in either normal or malignant human breast fibroblasts. It has been proposed that human ERβcx has a role similar to that suggested for ERβins in rat mammary glands, which is to antagonise ERα activity (Saji et al. 2001).

Previous studies have shown that ERβcx is expressed in breast cancer (Chu et al. 1997, Petersen et al. 1998, Omoto et al. 2002, Palmieri et al. 2002). However, there have been diverse reports regarding the potential role of ERβcx. Some evidence has shown that high levels of ERβcx mRNA expression are associated with tamoxifen-resistant and more aggressive breast cancers (Leygue et al. 1999, Speirs et al. 1999, Saji et al. 2002). In contrast, a reduced expression of ERβcx has been reported to be associated with metastatic breast tumours and those that have a high number of tumour-positive lymph nodes (Ahr et al. 2001, 2002). Moreover, vascular invasion has also been found to correlate significantly with an ERβcx-negative phenotype (Saji et al. 2002) and, recently, ERβcx expression has been associated with favourable response to endocrine therapy and prognostic outcome (Palmieri et al. 2004). The selective expression of ERβcx strongly suggests that splicing of the ERβ gene is regulated in a cell-specific manner. This is not the first report in which ERβcx and/or ERβ1 are expressed in populations of cells where there is no ERα. In the endometrium, ERβcx protein and RNA were expressed in decidual glands and stroma cells in the absence of ERα (Henderson et al. 2003) and in Sertoli cells of the testis there was expression of ERβcx but not ERβ1 (Saunders et al. 2002).

In the present study, ERβcx appears to be the predominant form of ERβ in fibroblasts from both normal and malignant adult mammary glands. Previous in vitro studies have shown that it is a very good repressor of ERα function at EREs (Ogawa et al. 1998) but the activity of ERβcx alone or in combination with either ERα or ERβ at ‘non-classical’ oestrogen-responsive sites, such as AP-1 and Sp1, has not been investigated (Paech et al. 1997). Since ERs mediate proliferation as well as differentiation, a more thorough look at which functions of ERα are influenced by ERβcx is needed in order to define the physiological role of ERβcx. In the present study, there was no detectable ERα in breast stroma. If ERβcx has a physiological function in the stroma, that function is not to inhibit ERα activity. The oestrogen-binding assay revealed that the forms of ERβ present in the 4S region of the sucrose gradient do not bind efficiently to radiolabelled oestradiol. This lack of oestrogen binding supports the PCR data that ERβcx, which has little or no oestrogen-binding activity, is more abundant than ERβ1 and indicates that ERβcx may antagonise ERβ1 activity. Consistent with this, we obtained data from transient transfection assays showing that oestrogen is inefficient in activating gene transcription from an ERE-containing reporter in the human breast fibroblasts, while the same promoter can be induced by BAG, an ERβ-specific ligand. Similarly, our data also showed that BAG, but not oestrogen, can induce the production of FGF7 from these fibroblasts.

The findings by Omoto et al. (1998) and Ogawa et al. (1998) that ERα function can be quenched by ERβcx raised the question as to whether measurement of ERβcx should be done as part of the diagnosis in breast cancer since it could identify some ERα-positive cancers which are resistant to tamoxifen. The present finding that ERβcx is also expressed in breast stroma means that for such
measurements to be of value, not only the expression level but also the cellular distribution of ERβ and variants would have to be considered in future diagnosis and studies of the human breast. Further studies on the regulation of ERβ splice variant expression and function in the stromal compartment will help in our understanding of mammary gland development and malignant transformation, and assist in the identification of novel targets for therapeutic intervention.

Acknowledgements

This research was supported by grants from the Cancer Research-UK and the Swedish Cancer Fund. We also wish to thank Christina Thulin-Andersson for skilful technical assistance.

References


Gomm J, Browne PJ, Coope RC & Coombes RC 1997 Separated human breast epithelial and myoepithelial cells have different growth factor requirements in vitro but can reconstitute normal breast lobuloalveolar structure. *Journal of Cellular Physiology* 171 11–19.


2001 Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. PNAS 98 646–651.


Zhang HZ, Bennett JM, Sunil N, Haslam SZ 2001 Estrogen mediates mammary epithelial cell proliferation in serum-free culture indirectly via mammary stroma-derived hepatocyte growth factor. Endocrinology 143 3427–3434.


Received 18 February 2004
Accepted 26 April 2004
Made available online as an Accepted Preprint 6 May 2004